Syndax Pharmaceuticals, Inc. Derivative Liability, Current
Syndax Pharmaceuticals, Inc. (SNDX) had Derivative Liability, Current of $0 as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2023-02-28
- 2022-12-31: Derivative Liability, Current $0.00.
- 2022-09-30: Derivative Liability, Current $0.00.
- 2021-12-31: Derivative Liability, Current $187.00K.
- 2015-12-31: Derivative Liability, Current $133.00K.
| Period end | Derivative Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2021-12-31 | $187.00K 10-K · filed 2023-02-28 |
| 2015-12-31 | $133.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |